Derived from the BW7756 mouse hepatoma that spontaneously arose in a C57/L mouse, this murine model of hepatocellular carcinoma (HCC) offers unparalleled insights for evaluating the efficacy and immuno-PD changes following anti-cancer immunotherapy treatment.
At Crown Bioscience, we understand the importance of having versatile and customizable models for your drug development endeavors. That’s why we offer the HEPA 1-6 model in both subcutaneous and orthotopic options. Whether you need to assess tumor growth, therapeutic response, or metastasis, our model provides the flexibility you require.
To facilitate disease progression tracking, we also offer a firefly luciferase tagged reporter line of the Hepa 1-6 model. With bioluminescent imaging, you can easily monitor tumor growth and response to treatment, enabling precise and real-time assessment.
Synonyms: HEPA 1-6, Hepa1-6
Hepa 1-6 is a murine model of hepatocellular carcinoma (HCC), derived from the BW7756 mouse hepatoma that spontaneously arose in a C57/L mouse(1). This cell line can be grown in the C57BL/6 mouse strain for in vivo testing. It is well-suited for evaulating the efficacy and immuno-PD changes following anti-cancer immunotherapy treatment. At CrownBio, the Hepa 1-6 model is available subcutaneously and orthotopically. In addition, a firefly luciferase tagged reporter line of Hepa 1-6 model is available, fascilitating disease progression tracking via bioluminescent imaging.
Response to Immune Checkpoint Inhibitors